

Manuscript word count: 2418

Abstract word count: 246

Display items: 4

Reference count: 54

Supplementary file: yes

Title: Gaps in the phenotype descriptions of ultra-rare genetic conditions: review and multi-center consensus reporting guidelines

Author list:

Ali AlMail^{1,2}, Ahmed Jamjoom^{1,3}, Amy Pan⁴, Min Yi Feng⁴, Vann Chau^{3,5}, Alissa D’Gama^{6,7,8}, Katherine Howell^{9,10}, Nicole S.Y. Liang^{4,11}, Amy McTague^{12,13}, Annapurna Poduri^{6,14}, Kimberly Wiltrout^{6,14}, IPCHiP Executive Committee*, Anne S. Bassett¹⁵, John Christodoulou¹⁰, Lucie Dupuis¹¹, Peter Gill³, Tess Levy¹⁶, Paige Siper¹⁶, Zornitza Stark^{10,17,18}, Jacob A.S. Vorstman^{15,19}, Catherine Diskin³, Natalie Jewitt³, Danielle Baribeau^{15,20,**}, Gregory Costain^{2,3,4,11,**}

¹Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

²Program in Genetics & Genome Biology, SickKids Research Institute, Toronto, Canada

³Department of Paediatrics, University of Toronto, Toronto, Canada

⁴Department of Molecular Genetics, University of Toronto, Toronto, Canada

⁵Division of Neurology, Hospital for Sick Children, Toronto, Canada

⁶Department of Neurology, Boston Children’s Hospital, Boston, MA, USA

⁷Division of Newborn Medicine, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, USA

⁸Department of Pediatrics, Harvard Medical School, Boston, MA, USA

⁹Department of Neurology, Royal Children’s Hospital, Melbourne, Australia

¹⁰Murdoch Children’s Research Institute, Melbourne, Australia

¹¹Division of Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Canada

¹²Department of Neurology, Great Ormond Street Hospital, London, UK

¹³Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK

¹⁴Department of Neurology, Harvard Medical School, Boston, MA, USA

¹⁵Department of Psychiatry, University of Toronto, Toronto, Canada

¹⁶Division of Psychiatry, Ichan School of Medicine at Mount Sinai, New York City, New York, United States of America

¹⁷Department of Paediatrics, University of Melbourne, Melbourne, Australia

¹⁸Victorian Clinical Genetics Service, Melbourne, Australia

¹⁹Department of Psychiatry, Hospital for Sick Children, Toronto, Canada

²⁰Autism Research Centre, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Canada

***IPCHiP Executive Committee members:** Nancy C Andrews, Alan H Beggs, John Christodoulou, J Helen Cross, Christian R Marshall, Kathryn N North, Stephen W Scherer, Neil J Sebire, Piotr Sliz

****Contact information:** Danielle Baribeau, MD, PhD, FRCPC, E-mail:

dbaribeau@hollandbloorview.ca; Gregory Costain, MD, PhD, FRCPC, E-mail:

gregory.costain@sickkids.ca

ABSTRACT

Background: Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-first ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear.

Methods: We identified reports published from 2017-2021 in ten genetics journals of novel Mendelian disorders ascertained genotype-first. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries.

Results: In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the six domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and “behavioural issues”, or about the type/nature of feeding problems. Follow-up reports (n=95) rarely addressed the limitations of the original reports. Reporting guidelines were developed for each domain.

Conclusion: Phenotype information relevant to clinical management, genetic counseling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. Use of the proposed guidelines could improve phenotype reporting in the genomic era.

KEYWORDS

Phenotype, Ultra-rare genetic conditions, Genome sequencing, Natural history, Mendelian genetic diseases

1 **INTRODUCTION**

2 Genome-wide sequencing and genetic matchmaker services have created a new paradigm for
3 Mendelian disorder delineation.¹⁻³ Compared to prior decades, when syndrome identification was
4 predominantly phenotype driven, there is now an increasing focus on genotype-first ascertainment
5 and on generating functional evidence or usage of non-human model systems to support the
6 disease-variant/gene association. There are no well-defined nor broadly accepted minimum
7 standards for phenotype descriptions of putative novel disorders with multisystem manifestations
8 and/or a neurodevelopmental component. Variability in the consistency of phenotyping and
9 describing of findings is problematic. This variability can be exacerbated by individual sites each
10 contributing only a single patient to an international case-series study, or the extraction of
11 phenotype data from laboratory test requisitions.

12
13 After a first description of a novel Mendelian disorder is published, patients soon thereafter begin
14 to be diagnosed via clinical genome-wide sequencing.⁴⁻⁶ These individually ultra-rare⁷ conditions
15 are collectively important contributors to the burden of genetic disease in the population.⁸ The
16 typical benefits of a molecular genetic diagnosis^{7,9} are attenuated when there is limited information
17 available to inform genotype-phenotype correlation, natural history, prognostication, and
18 anticipatory care. A key consideration in the assessment of ultra-rare conditions for potential
19 “precision therapy” development is the degree to which the patient’s clinical trajectory can be
20 anticipated.^{10,11} Families who are amongst the first to receive a diagnosis of an ultra-rare genetic
21 disorder have endorsed frustration with the perceived lack of information and support.^{12,13}
22 Similarly, clinicians face the same informational barrier, which impacts their abilities to care for
23 and counsel patients and their families.¹⁴

24
25 Published expert opinions, survey data, reviews, and data from patient and family focus groups
26 highlight key informational areas germane to the natural history of ultra-rare genetic diseases.¹⁴⁻²⁴
27 We assessed the breadth and depth of phenotype reporting in contemporary descriptions of novel
28 Mendelian genetic diseases across six priority domains: (I) Development, cognition, and mental
29 health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and
30 quality of life; (V) Adulthood; and (VI) Epilepsy. We also assessed in a similar manner follow-up
31 reports appearing in the years following an initial report. These findings provided the impetus for,
32 and guided the development of, the proposed new PHELIX (PHENotype Listing fix) reporting
33 guideline checklists.

34 **MATERIALS AND METHODS**

35 **Systematic review**

36 We utilized DistillerSR Version 2.35 for searching, screening, and data extraction (DistillerSR Inc,
37 2022; accessed January 2022 – January 2023). We identified all first reports of novel genetic
38 conditions discovered through genotype-first ascertainment that result in multisystem and/or
39 neurodevelopmental phenotypes, which were published in one of ten genetics journals (*American*
40 *Journal of Human Genetics*, *American Journal of Medical Genetics Part A*, *Clinical Genetics*,
41 *European Journal of Human Genetics*, *Genetics in Medicine*, *Genome Medicine*, *Human*
42 *Molecular Genetics*, *Journal of Medical Genetics*, *Nature Genetics*, *PLoS Genetics*) during a 5-
43 year period (1 January 2017 - 31 December 2021). The search executed on January 3, 2022,
44 identified 3,243 articles (Supplementary Table 1; Supplementary Figure 1). Exclusion criteria
45 were: (i) prenatal or neonatal lethal phenotype, (ii) case report or description of a single family,
46 (iii) new gene for a known clinical syndrome (e.g., Joubert syndrome, Noonan syndrome), (iv)
47 chromosome disorder with non-recurrent breakpoints that did not definitively implicate a specific
48 gene, (v) potential genotype-phenotype expansion rather than a novel disorder. We also excluded
49 large-scale gene discovery efforts in populations with common complex diseases and/or clinical
50 testing laboratory cohort studies, where the *a priori* expectation for detailed phenotype
51 descriptions was low. After both title and abstract screening and full-text review stages, n=200
52 reports describing 199 distinct monogenic conditions met the inclusion criteria (two reports of a
53 novel condition were published at the same time; Supplementary Figure 1). For the subset of 25
54 genetic conditions first described in 2017, we performed an additional search using DistillerSR on
55 June 1, 2022 (Supplementary Table 1) to identify subsequent published case descriptions (total
56 n=95; Supplementary Figure 2). Reference review and additional internet searching did not
57 identify any other “follow-up” reports.

58

59 **Data extraction and analysis**

60 For each published article (n=295), study team members (authors A.A., A.J., A.P., M.Y.F.)
61 adjudicated the phenotype data pertaining to six priority domains [(I) Development, cognition, and
62 mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain,
63 sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy] using a custom designed data
64 extraction form (Supplementary Tables 3, 5, 6). Domains I-VI were included based on the study
65 team’s clinical experience and review of the aforementioned published expert opinions, survey
66 data, reviews, and data from patient and family focus groups.¹⁴⁻²⁴ Data for Domains V-VI were
67 extracted separately from Domains I-IV. The total 46-item form was developed by members of the
68 study team (authors A.A., A.J., C.D., N.J., D.B., G.C.) with clinical expertise in medical genetics,
69 psychiatry, development, general paediatrics, paediatric palliative care, paediatric complex care,
70 and paediatric hospitalist medicine. Each domain was associated with multiple issue-specific
71 items. A separate overall qualitative assessment of reporting quality (“strong”, “adequate”,
72 “superficial/deficient”, “absent”, or “not applicable”) was also assigned for Domains I-IV.
73 Descriptive statistics were calculated using Microsoft Excel.

74

75 **Development of phenotype reporting guidelines through a modified Delphi process**

76 Medical experts from member institutions of the International Precision Child Health Partnership
77 (IPCHiP) participated in a modified Delphi process.²⁵ IPCHiP institutions included: Murdoch
78 Children’s Research Institute/Royal Children’s Hospital (Melbourne, Australia), The Hospital for
79 Sick Children (SickKids®; Toronto, Ontario, Canada), University College London/Greater

80 Ormond Street Hospital (London, United Kingdom), and Boston Children’s Hospital
81 (Massachusetts, USA).^{26,27} At the suggestion of the original study team members, additional
82 expertise was sought in: (i) neuropsychological assessment and cognitive phenotyping (via Seaver
83 Autism Center for Research and Treatment; New York, USA),²⁸⁻³⁰ and (ii) adult phenotyping (via
84 University Health Network; Toronto, Ontario, Canada).^{31,32} Authors J.C., L.D., P.G., T.L., P.S.,
85 Z.S., J.A.S.V., C.D., N.J., D.B. contributed to the initial refinement of guidelines for Domains I-
86 V. We sent out three electronic surveys to the above authors (minimum engagement rate >50%)
87 over a five-month period to define and prioritize the reporting criteria. We then hosted an online
88 meeting that incorporated independent voting on inclusion/exclusion of each draft item. The
89 meeting was recorded, to allow for asynchronous viewing by those expert volunteers who were
90 unable to attend in real-time. Authors V.C., A.D., K.H., N.S.Y.L., A.T., A.P., K.W. contributed to
91 the initial refinement of guidelines for Domain VI (Epilepsy). Similarly, we used a series of two
92 electronic surveys to define and prioritize the reporting criteria. All authors reviewed, revised, and
93 ultimately approved the reporting guideline checklists for Domains I-VI reported herein. The
94 guideline checklists will be uploaded to the EQUATOR (Enhancing the QUALity and
95 Transparency Of health Research) Network website (<https://www.equator-network.org/>) as the
96 PHELIX_General (Table 1) and the PHELIX_Epilepsy checklists (Table 2).

97 **RESULTS**

98 **Contemporary descriptions of new syndromes are often lacking in phenotype details**

99 The 200 reports of 199 newly discovered genetic disorders included phenotype descriptions for a
100 total of 1,856 study participants (median: 7/report, range 2-42). Features of the reports (year and
101 journal of publication) and of the participants (age) are summarized in Supplementary Tables 2-
102 3). The overall qualitative assessment of reporting was deemed “superficial/deficient” or “absent”
103 in 87% (Domain I: Development, cognition, and mental health) to 98% (Domain IV: Pain, sleep,
104 and quality of life) of papers (Figure 1). Five (2.5% of 200) reports were deemed “strong” in any
105 single domain (pertaining to the genetic conditions associated with variants in the genes
106 *ADARBI*³³, *GNAII*³⁴, *NCAPG2*³⁵, *PCDHGC4*³⁶, and *SPTBNI*³⁷). No reports were deemed
107 “strong” in their reporting across each of Domains I-IV. The year and journal of publication were
108 not associated with overall quality assessment of phenotype reporting (data not shown).

109
110 Item-specific data supported the overall qualitative assessments of reporting quality (Figure 2,
111 Supplementary Table 3, Supplementary Figures 3-4). While 97% of papers mentioned
112 developmental concerns in study participants, 21% provided details about cognitive abilities for
113 all the participants and a sole paper³⁸ reported results from formal cognitive assessments for all
114 participants (Figure 2a, Supplementary Table 4). A common issue was that individuals were
115 identified as having “developmental delay” without further elaboration. Similarly, of the papers
116 that reported neuropsychiatric and behavioural issues in study participants, less than 5% of papers
117 provided details for all participants regarding type/diagnosis, symptom severity, and/or nature of
118 the assessments (Figure 2a, Supplementary Table 3). Of the papers that reported on the presence
119 of feeding difficulties (Figure 2b), 8% consistently reported on the type/nature of feeding issues
120 and current means of feeding (Figure 2b, Supplementary Table 3). Growth parameters at birth were
121 often reported, but 6% of papers reported on two or more growth measurements post-birth to allow
122 for assessment of growth trajectories (Figure 2b, Supplementary Table 4). Nearly half of all papers
123 made no mention of participants’ medications or treatment trials, or of the absence thereof (Figure
124 2c). The presence or absence of adverse effects of treatments were explicitly mentioned in just
125 21% of reports (Figure 2c).

126
127 Domain V (Adulthood) was assessed in the subset of reports that included at least one adult
128 individual (n=63; adult defined as age ≥ 18 years) (Supplementary Figure 1; Supplementary Table
129 6). Domain VI (Epilepsy) was assessed in the subset of reports that included at least one study
130 participant with seizures/epilepsy (n=85) (Supplementary Figure 1; Supplementary Table 7).
131 Consistent with the findings regarding Domains I-IV, most items were inconsistently or never
132 reported (Supplementary Figures 3-4). For example, papers rarely described proxies for adult
133 functioning such as educational achievement or employment, nor the anti-seizure treatments for
134 individuals with epilepsy.

136 **Follow-up reports do not consistently address initial gaps in phenotype descriptions**

137 Regarding the 25 genetic conditions first described in 2017, the 95 “follow-up” reports included
138 phenotype descriptions for an additional 334 study participants (median: 1 per report, range 1-25).
139 The overall qualitative assessment of reporting was similarly classified as “absent” or
140 “superficial/deficient” in 81% (Domain III: Medication use and treatment history) to 99% (Domain
141 IV: Pain, sleep, and quality of life) of papers (Figure 1, Supplementary Table 4), with no significant
142 differences between the original and the follow-up reports. Eleven reports were deemed “strong”

143 in any single domain (pertaining to the genetic conditions associated with variants in the eight
144 genes *CAMK2A*³⁹, *CAMK2B*^{39,40}, *DHX30*⁴¹, *OTUD6B*⁴², *PPP3CA*⁴³, *UBTF*^{44,45}, *WDR26*^{46,47}, and
145 *YY1*⁴⁸). No reports were deemed “strong” in their reporting across each of domains I-IV. Item-
146 specific data are summarized in Supplementary Table 4.

147

148 **Consensus phenotype reporting guidelines**

149 Guideline checklists to enhance the reporting of phenotype data for ultra-rare genetic conditions
150 were developed through a modified Delphi process²⁵ and informed by the findings above
151 (Supplementary Table 8). Specifically, items were included based on their superficial/deficient
152 reporting in the literature to date, and on the recommendations of expert collaborators as being
153 data that are both important to capture and feasible to obtain by researchers. The finalized checklist
154 of 33 items across 9 categories is presented in Table 1 (PHELIX_General). To showcase how these
155 guidelines could be expanded over time, additional items specific to epilepsy phenotype reporting
156 are listed in Table 2 (PHELIX_Epilepsy). Extended versions with examples are provided in
157 Supplementary Tables 9-10.

158 **DISCUSSION**

159 Our results reveal that phenotype information relevant to clinical management, genetic counseling,
160 and the stated priorities of patients and families, is lacking for many newly described genetic
161 diseases. Although most published reports acknowledged the key phenotype domains assessed,
162 few original or follow-up reports included clinically relevant details. To address this issue, we
163 propose reporting guideline checklists for use by researchers and journals. Use of these guidelines
164 could improve phenotype reporting in the era of genotype-first and matchmaker service-driven
165 reports of novel syndromes. Decision making about precision genetic or other therapy
166 development, including the potential for n=1 trials, may be contingent on our understanding (or
167 lack thereof) of the natural history of a given ultra-rare genetic disease.^{10,11,49}

168
169 Reasons for under-reporting phenotype data are likely multiple and complex. First, these data may
170 not be readily available to the referring clinician or laboratory collaborators, and “phenotyping is
171 hard,”⁵⁰ especially for older individuals with extensive past histories. Review of lifetime medical
172 records, and/or a brief, targeted interview with patients and/or their caregiver(s), should be
173 sufficient to gather most of the information outlined in Tables 1-2. Second, these data may not be
174 requested by the coordinating research team that is leading the publication effort. In our
175 experience, many groups design their own data collection forms that ask for no or only general
176 details regarding issues outside of that group’s specific phenotype(s) of interest. Third, unlike for
177 example DNA sequencing methods, there are no defined minimum reporting standards for
178 phenotyping to guide peer reviewers and journal editors. Finally, there may be a belief that
179 phenotype reporting in initial descriptions of novel genetic diseases is less important than
180 establishing an association between variation in the gene and (any) disease phenotype. Although
181 the hope may be that future reports will then describe many more individuals and include detailed
182 phenotype data, we did not find evidence that this is consistently happening in practice in a timely
183 manner.

184
185 We recognize several limitations of our review and guideline development methods. We selected
186 only ten top-tier genetics journals for our systematic review. The generalizability of our findings
187 to reports published in other specialty-specific or organ system-specific journals is unclear. Out of
188 necessity given the lack of validated tools, we created a new data collection questionnaire to assess
189 the reporting of phenotype data and relied on subjective assessments from raters for some items.
190 We selected broad phenotype domains based on our combined clinical experiences and the
191 published literature. Ours was a paediatrics-focused effort, reflecting the phenotypes that are
192 currently driving most Mendelian gene discovery efforts. Other groups may develop and add-on
193 reporting criteria for additional specific phenotype elements, as we did for epilepsy, and continue
194 to refine the general adult phenotype elements (Table 2). We also restricted our initial focus to
195 cross-sectional reporting, and additional guidance will be needed for evaluating within-individual
196 natural history. Finally, our reporting guidelines have not yet been applied prospectively to assess
197 feasibility and utility.

198
199 We propose minimum standards for phenotype descriptions of putative novel disorders with
200 multisystem manifestations and/or a neurodevelopmental component in children. Further
201 refinement of our proposed reporting guidelines is an important consideration. Collecting
202 additional input from key stakeholders (e.g., rare disease organizations, journal editors) should be
203 coupled with attempts to better integrate technologies for systematic phenotype collection and data

204 sharing.^{21,51} Improved reporting of phenotype aspects like craniofacial morphology (“dysmorphic
205 features”)⁵² could help with interpreting variants of uncertain significance and assessing
206 phenotypic “fit”.^{53,54} The aim of the PHELIX guideline checklists is to decrease the variability in
207 the consistency of phenotyping and description of findings, and thereby enhance the ongoing
208 clinical care of individuals with genetic conditions.

209 **Table 1.** Phenotype reporting checklist (PHELIX_General version 1.0).
210

Phenotype Category	Recommendation Category	Specific Recommendation For Inclusion In Report
1. Development and Cognition	Strongly recommended	i. Standard and specific diagnostic term(s) for cognitive or developmental issue(s) ii. Level of cognitive functioning or degree of developmental delay iii. Age of attaining major milestones iv. Quantitative results from psychometric testing OR explicit acknowledgement that these results were not available
	Optional, but encouraged	v. Narrative summary describing progression / change in cognitive or development issue(s) over time.
2. Behaviour and Neuropsychiatric Conditions	Strongly recommended	i. Standard and specific diagnostic term(s) for behavioural issues
	Optional, but encouraged	ii. Reported functional impact of behavioural/psychiatric condition iii. Age at diagnosis and/or age at first concern for behavioural issues iv. Impact of treatments / interventions, as reported by individuals, families, and/or clinicians
3. Other Medical Conditions	Strongly recommended	i. Major medical conditions ii. Presence or absence of issues in the following areas (if potentially associated with the condition under study): <ul style="list-style-type: none"> • Visual acuity and field of vision • Hearing ability • Speech/communication styles • Continence/toileting • Ambulation
4. Feeding Issues	Strongly recommended	i. Functional impact of feeding issues ii. Current feeding method (e.g., oral, gastrostomy tube)
	Optional, but encouraged	iii. Age at first concern for feeding issues iv. Interventions and supports for feeding issues (e.g., feeding tube support)
5. Growth	Strongly recommended	i. Birth growth measurements AND gestational age-corrected centiles

		ii. Growth measurements (absolute values and z-scores) at two or more post-birth timepoints (where possible)
6. Medication and Treatment History	Optional, but encouraged	i. Details of efficacious treatment(s) ii. Severe adverse events / reactions
7. Pain, Sleep, and Quality of Life	Optional, but encouraged	i. Presence or absence of pain / neuroirritability ii. Presence or absence of abnormal sleep patterns / sleep disturbance iii. Qualitative description of proxies for quality of life, via patient and/or caregiver report iv. Direct assessment of quality of life using established measure(s), via patient and/or caregiver report
8. Indicators of adult functional outcome	Strongly recommended	i. Age at which the adult was last seen/phenotyped ii. Description of educational achievement iii. Nature of any employment (past and/or present)
	Optional, but encouraged	iv. Relationship status (past and/or present) v. Reproductive history
9. Other	Strongly recommended	i. Confirmation of informed consent to participate in the research study and to include the above phenotype information, for each participant ii. Distinguish between “not assessed” and “assessed and not present,” for every aspect of a phenotype described in the report and for each participant iii. Description of how phenotyping was performed (e.g., direct assessment by study team member(s), review of medical records, information provided on testing requisition), for each participant iv. Use of standard phenotype labels (e.g., HPO, ICD-11) to standardize reporting, for each participant. v. [For deceased participants] Cause of death

211 Abbreviations: HPO, Human Phenotype Ontology; ICD-11, International Classification of
212 Diseases 11th Revision

213 **Table 2.** Phenotype reporting recommendations for unprovoked seizures/epilepsy in individuals
 214 with newly described multisystem and/or neurodevelopmental Mendelian disorders
 215 (PHELIX_Epilepsy version 1.0).

Phenotype Subcategory	Recommendation Category	Specific Recommendation For Inclusion In Report
1. Epilepsy syndrome and severity	Strongly recommended	i. Seizure type(s) (per ILAE) ii. Epilepsy syndrome(s) (per ILAE) iii. Findings that support the diagnosis of the epilepsy syndrome(s) (e.g., specific EEG findings) iv. Seizure frequency at last clinical assessment v. Qualitative description of overall epilepsy severity
	Optional, but encouraged	vi. Number of seizures requiring hospitalization in specific timeframe (e.g., last year)
2. Pharmacological interventions	Strongly recommended	i. Current and past medication name(s) ii. Perceived impact on seizure control
	Optional, but encouraged	iii. Dose iv. Duration of treatment trial v. Adverse effects/events due to the intervention
3. Non-pharmacological interventions	Strongly Recommended	i. Intervention / procedure details (e.g., ketogenic diet, neurosurgery) ii. Perceived impact on seizure control
	Optional, but encouraged	iii. Adverse effects/events due to the intervention
4. Brain imaging and EEG findings	Strongly recommended	i. Brain imaging findings (including age(s) at time of study) ii. EEG findings (including age(s) at time of study)
	Optional, but encouraged	iii. Clarification if brain imaging and/or EEG data were directly reviewed by members of the study team (versus only report details extracted from medical record)
5. Other	Optional, but encouraged	i. Narrative summary of the progression of the individual's seizure(s)/epilepsy phenotype over time ii. Narrative summary of the progression of the individual's non-epilepsy phenotype over time (e.g., see PHELIX_General guidelines)

216 Abbreviations: EEG, electroencephalogram; ILAE, International League Against Epilepsy

217 **ACKNOWLEDGMENTS**

218 Funding was provided by the SickKids Research Institute, the Canadian Institutes of Health
219 Research (Funding Reference Number: PJT186240), and the University of Toronto McLaughlin
220 Centre. IPCHiP is supported in part by SickKids Foundation donors including Jamie and Patsy
221 Anderson and the Feiga Bresver Academic Foundation. D.B. also acknowledges the support of her
222 research time at Holland Bloorview by the Arthur Family Foundation. J.A.S.V. holds the SickKids
223 Psychiatry Associates Chair in Developmental Psychopathology at The Hospital for Sick Children.
224 Research conducted at the Murdoch Children’s Research Institute was supported by the Victorian
225 Government’s Operational Infrastructure Support Program. The Chair in Genomic Medicine
226 awarded to J.C. is generously supported by The Royal Children’s Hospital Foundation. These
227 funders played no role in study design, data collection, analysis and interpretation of data, or the
228 writing of this manuscript.

229
230 **CRedit AUTHOR STATEMENT**

231 Conceptualization: D.B., G.C.
232 Methodology: A.A., A.J., C.D., N.J., D.B., G.C.
233 Software: N/A
234 Validation: A.A., A.J., A.P., M.Y.F., G.C.
235 Formal analysis: A.A.
236 Investigation: A.A., A.J., A.P., M.Y.F., V.C., A.D., K.H., N.S.Y.L., A.T., A.P., K.W., A.S.B., J.C.,
237 L.D., P.G., T.L., P.S., Z.S., J.A.S.V., C.D., N.J., D.B., G.C.
238 Resources: G.C.
239 Data curation: N/A
240 Writing – original draft: A.A., A.J., D.B., G.C.
241 Writing – review & editing: A.P., M.Y.F., V.C., A.D., K.H., N.S.Y.L., A.T., A.P., K.W., A.S.B.,
242 J.C., L.D., P.G., T.L., P.S., Z.S., J.A.S.V., C.D., N.J.
243 Visualization: A.A., A.J.
244 Supervision: L.D., P.G., G.C.
245 Project administration: A.A., A.J., D.B., G.C.
246 Funding acquisition: G.C.

247
248 **DECLARATION OF INTERESTS**

249 D.B. has received research funds from MapLight Therapeutics. K.W. has consulted for Stoke
250 Therapeutics. J.A.S.V. has served as a consultant for NoBias Therapeutics Inc. and has received
251 speaker fees for Henry Stewart Talks Ltd. These relationships did not influence content of this
252 manuscript but are disclosed for potential future considerations. The remaining authors declare no
253 financial or non-financial competing interests.

254
255 **DATA AVAILABILITY STATEMENT**

256 The datasets analysed during the current study are available from the corresponding authors on
257 reasonable request.

REFERENCES

- 258
259
260 1. Bamshad MJ, Nickerson DA, Chong JX. Mendelian Gene Discovery: Fast and Furious
261 with No End in Sight. *Am J Hum Genet.* 2019;105(3):448-455.
262 2. Boycott KM, Hartley T, Biesecker LG, et al. A Diagnosis for All Rare Genetic Diseases:
263 The Horizon and the Next Frontiers. *Cell.* 2019;177(1):32-37.
264 3. Boycott KM, Azzariti DR, Hamosh A, Rehm HL. Seven years since the launch of the
265 Matchmaker Exchange: The evolution of genomic matchmaking. *Hum Mutat.*
266 2022;43(6):659-667.
267 4. Bick D, Jones M, Taylor SL, Taft RJ, Belmont J. Case for genome sequencing in infants
268 and children with rare, undiagnosed or genetic diseases. *J Med Genet.* 2019;56(12):783-
269 791.
270 5. Australian Genomics Health Alliance Acute Care F, Lunke S, Eggers S, et al. Feasibility
271 of Ultra-Rapid Exome Sequencing in Critically Ill Infants and Children With Suspected
272 Monogenic Conditions in the Australian Public Health Care System. *JAMA.*
273 2020;323(24):2503-2511.
274 6. Costain G, Cohn RD, Scherer SW, Marshall CR. Genome sequencing as a diagnostic test.
275 *CMAJ.* 2021;193(42):E1626-E1629.
276 7. Costain G, Walker S, Marano M, et al. Genome Sequencing as a Diagnostic Test in
277 Children With Unexplained Medical Complexity. *JAMA Netw Open.*
278 2020;3(9):e2018109.
279 8. Haque B, Khan T, Ushcatz I, et al. Contemporary aetiologies of medical complexity in
280 children: a cohort study. *Arch Dis Child.* 2023;108(2):147-149.
281 9. Costain G, Chow EW, Ray PN, Bassett AS. Caregiver and adult patient perspectives on
282 the importance of a diagnosis of 22q11.2 deletion syndrome. *J Intellect Disabil Res.*
283 2012;56(6):641-651.
284 10. Pena LDM, Burrage LC, Enns GM, et al. Contributions from medical geneticists in
285 clinical trials of genetic therapies: A points to consider statement of the American
286 College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2023;25(6):100831.
287 11. Gleeson JG, Bennett CF, Carroll JB, et al. Personalized antisense oligonucleotides 'for
288 free, for life' - the n-Lorem Foundation. *Nat Med.* 2023;29(6):1302-1303.
289 12. Fanos JH. New "first families": the psychosocial impact of new genetic technologies.
290 *Genet Med.* 2012;14(2):189-190.
291 13. Lee W, Luca S, Costain G, et al. Genome sequencing among children with medical
292 complexity: What constitutes value from parents' perspective? *J Genet Couns.*
293 2022;31(2):523-533.
294 14. Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of
295 physicians regarding the diagnosis of rare diseases: a questionnaire-based study in
296 Belgium. *Orphanet J Rare Dis.* 2019;14(1):99.
297 15. Diskin C, Malik K, Gill PJ, et al. Research priorities for children with neurological
298 impairment and medical complexity in high-income countries. *Dev Med Child Neurol.*
299 2021.
300 16. Nelson KE, Finlay M, Huang E, et al. Clinical characteristics of children with severe
301 neurologic impairment: A scoping review. *J Hosp Med.* 2023;18(1):65-77.


- 302 17. Gill PJ, Bayliss A, Sozer A, et al. Patient, Caregiver, and Clinician Participation in
303 Prioritization of Research Questions in Pediatric Hospital Medicine. *JAMA Netw Open*.
304 2022;5(4):e229085.
- 305 18. Jacquemont S, Huguot G, Klein M, et al. Genes To Mental Health (G2MH): A
306 Framework to Map the Combined Effects of Rare and Common Variants on Dimensions
307 of Cognition and Psychopathology. *Am J Psychiatry*. 2022;179(3):189-203.
- 308 19. Commission on Novel Technologies for Neurodevelopmental Copy Number V.
309 Neurodevelopmental copy-number variants: A roadmap to improving outcomes by
310 uniting patient advocates, researchers, and clinicians for collective impact. *Am J Hum*
311 *Genet*. 2022;109(8):1353-1365.
- 312 20. Hanly C, Shah H, Au PYB, Murias K. Description of neurodevelopmental phenotypes
313 associated with 10 genetic neurodevelopmental disorders: A scoping review. *Clin Genet*.
314 2021;99(3):335-346.
- 315 21. Jacobsen JOB, Baudis M, Baynam GS, et al. The GA4GH Phenopacket schema defines a
316 computable representation of clinical data. *Nat Biotechnol*. 2022;40(6):817-820.
- 317 22. McTague A, Brunklaus A, Barcia G, et al. Defining causal variants in rare epilepsies: an
318 essential team effort between biomedical scientists, geneticists and epileptologists. *Eur J*
319 *Med Genet*. 2022;65(7):104531.
- 320 23. Perlman P, Vorstman J, Hoang N, et al. Support to caregivers who have received genetic
321 information about neurodevelopmental and psychiatric vulnerability in their young
322 children: A narrative review. *Clin Genet*. 2023;104(2):163-173.
- 323 24. Baribeau DA, Hoang N, Selvanayagam T, et al. Developmental implications of genetic
324 testing for physical indications. *Eur J Hum Genet*. 2022;30(11):1297-1300.
- 325 25. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research
326 reporting guidelines. *PLoS Med*. 2010;7(2):e1000217.
- 327 26. Morton SU, Christodoulou J, Costain G, et al. Multicenter Consensus Approach to
328 Evaluation of Neonatal Hypotonia in the Genomic Era: A Review. *JAMA Neurol*.
329 2022;79(4):405-413.
- 330 27. D'Gama AM, Mulhern S, Sheidley BR, et al. Evaluation of the feasibility, diagnostic
331 yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-
332 STEPS): an international, multicentre, pilot cohort study. *Lancet Neurol*. 2023;22(9):812-
333 825.
- 334 28. Levy T, Lerman B, Halpern D, et al. CHAMP1 disorder is associated with a complex
335 neurobehavioral phenotype including autism, ADHD, repetitive behaviors and sensory
336 symptoms. *Hum Mol Genet*. 2022;31(15):2582-2594.
- 337 29. Levy T, Foss-Feig JH, Betancur C, et al. Strong evidence for genotype-phenotype
338 correlations in Phelan-McDermid syndrome: results from the developmental
339 synaptopathies consortium. *Hum Mol Genet*. 2022;31(4):625-637.
- 340 30. Tang L, Levy T, Guillory S, et al. Prospective and detailed behavioral phenotyping in
341 DDX3X syndrome. *Mol Autism*. 2021;12(1):36.
- 342 31. Butcher NJ, Chow EW, Costain G, Karas D, Ho A, Bassett AS. Functional outcomes of
343 adults with 22q11.2 deletion syndrome. *Genet Med*. 2012;14(10):836-843.
- 344 32. Malecki SL, Van Mil S, Graffi J, et al. A genetic model for multimorbidity in young
345 adults. *Genet Med*. 2020;22(1):132-141.

- 346 33. Tan TY, Sedmik J, Fitzgerald MP, et al. Bi-allelic ADARB1 Variants Associated with
347 Microcephaly, Intellectual Disability, and Seizures. *Am J Hum Genet.* 2020;106(4):467-
348 483.
- 349 34. Muir AM, Gardner JF, van Jaarsveld RH, et al. Variants in GNAI1 cause a syndrome
350 associated with variable features including developmental delay, seizures, and hypotonia.
351 *Genet Med.* 2021;23(5):881-887.
- 352 35. Khan TN, Khan K, Sadeghpour A, et al. Mutations in NCAPG2 Cause a Severe
353 Neurodevelopmental Syndrome that Expands the Phenotypic Spectrum of
354 Condensinopathies. *Am J Hum Genet.* 2019;104(1):94-111.
- 355 36. Iqbal M, Maroofian R, Cavdarli B, et al. Biallelic variants in PCDHGC4 cause a novel
356 neurodevelopmental syndrome with progressive microcephaly, seizures, and joint
357 anomalies. *Genet Med.* 2021;23(11):2138-2149.
- 358 37. Cousin MA, Creighton BA, Breau KA, et al. Pathogenic SPTBN1 variants cause an
359 autosomal dominant neurodevelopmental syndrome. *Nat Genet.* 2021;53(7):1006-1021.
- 360 38. Harel T, Levy-Lahad E, Daana M, et al. Homozygous stop-gain variant in LRRC32,
361 encoding a TGFbeta receptor, associated with cleft palate, proliferative retinopathy, and
362 developmental delay. *Eur J Hum Genet.* 2019;27(8):1315-1319.
- 363 39. Akita T, Aoto K, Kato M, et al. De novo variants in CAMK2A and CAMK2B cause
364 neurodevelopmental disorders. *Ann Clin Transl Neurol.* 2018;5(3):280-296.
- 365 40. Dwyer BK, Veenma DCM, Chang K, Schulman H, Van Woerden GM. Case Report:
366 Developmental Delay and Acute Neuropsychiatric Episodes Associated With a de novo
367 Mutation in the CAMK2B Gene (c.328G>A p.Glu110Lys). *Front Pharmacol.*
368 2022;13:794008.
- 369 41. Mannucci I, Dang NDP, Huber H, et al. Genotype-phenotype correlations and novel
370 molecular insights into the DHX30-associated neurodevelopmental disorders. *Genome*
371 *Med.* 2021;13(1):90.
- 372 42. Romero-Ibarguengoitia ME, Cantu-Reyna C, Gutierrez-Gonzalez D, Cruz-Camino H,
373 Gonzalez-Cantu A, Sanz Sanchez MA. Comparison of Genetic Variants and
374 Manifestations of OTUD6B-Related Disorder: The First Mexican Case. *J Investig Med*
375 *High Impact Case Rep.* 2020;8:2324709620957777.
- 376 43. Mizuguchi T, Nakashima M, Kato M, et al. Loss-of-function and gain-of-function
377 mutations in PPP3CA cause two distinct disorders. *Hum Mol Genet.* 2018;27(8):1421-
378 1433.
- 379 44. Toro C, Hori RT, Malicdan MCV, et al. A recurrent de novo missense mutation in UBTF
380 causes developmental neuroregression. *Hum Mol Genet.* 2018;27(4):691-705.
- 381 45. Sedlackova L, Lassuthova P, Sterbova K, et al. UBTF Mutation Causes Complex
382 Phenotype of Neurodegeneration and Severe Epilepsy in Childhood. *Neuropediatrics.*
383 2019;50(1):57-60.
- 384 46. Cospain A, Schaefer E, Faucher M, et al. Skraban-Deardorff syndrome: Six new cases
385 of WDR26-related disease and expansion of the clinical phenotype. *Clin Genet.*
386 2021;99(5):732-739.
- 387 47. Pavinato L, Trajkova S, Grosso E, et al. Expanding the clinical phenotype of the ultra-
388 rare Skraban-Deardorff syndrome: Two novel individuals with WDR26 loss-of-function
389 variants and a literature review. *Am J Med Genet A.* 2021;185(6):1712-1720.

- 390 48. Carminho-Rodrigues MT, Steel D, Sousa SB, et al. Complex movement disorder in a
391 patient with heterozygous YY1 mutation (Gabriele-de Vries syndrome). *Am J Med Genet*
392 *A.* 2020;182(9):2129-2132.
- 393 49. Juando-Prats C, James E, Bilder DA, et al. DRAVET ENGAGE. Parent caregivers of
394 children with Dravet syndrome: Perspectives, needs, and opportunities for clinical
395 research. *Epilepsy Behav.* 2021;122:108198.
- 396 50. Collins C. Phenotype with a side of genotype, please: Patients, parents and priorities in
397 rare genetic disease. *Appl Transl Genom.* 2016;8:42-44.
- 398 51. Girdea M, Dumitriu S, Fiume M, et al. PhenoTips: patient phenotyping software for
399 clinical and research use. *Hum Mutat.* 2013;34(8):1057-1065.
- 400 52. Biesecker LG. An introduction to standardized clinical nomenclature for dysmorphic
401 features: the Elements of Morphology project. *BMC Med.* 2010;8:56.
- 402 53. Elliott AM, Adam S, du Souich C, et al. Genome-wide sequencing and the clinical
403 diagnosis of genetic disease: The CAUSES study. *HGG Adv.* 2022;3(3):100108.
- 404 54. Mak CC, Leung GK, Mok GT, et al. Exome sequencing for paediatric-onset diseases:
405 impact of the extensive involvement of medical geneticists in the diagnostic odyssey.
406 *NPJ Genom Med.* 2018;3:19.
407

408 **FIGURES**

409 **Figure 1.** Global assessments of the quality of reporting of phenotype details germane to Domains
410 I-IV. Dark blue = initial reports (n=200 papers), and light blue = follow-up reports regarding the
411 25 genetic conditions initially described in 2017 (n=95 papers). There were no significant
412 differences in the distribution of overall quality ratings between the initial and follow-up reports,
413 for any of the domains (Fisher's exact tests, $p>0.05$). See text for details.



414 **Figure 2.** Selected item-level findings from a systematic review of phenotype reporting in n=200
415 descriptions of novel genetic syndromes. Domain I, (b) Domain II, (c), Domain III. See
416 Supplementary Table 3 for details.

